Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy

Annals of the Rheumatic Diseases

Volumn 64, Issue 4, 2005, Pages 529-536

  Kruithof, E ^a   Baeten, D ^a   Van Den Bosch, F ^a   Mielants, H ^a   Veys, E ^a   De Keyser, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY INFILTRATE; JOINT BIOPSY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONDYLOARTHROPATHY; SYNOVIUM; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOPSY; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SPONDYLARTHROPATHIES; SYNOVIAL MEMBRANE; SYNOVITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16344381733     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.018549     Document Type: Article

References (27)

1. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
2. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
3. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
4. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
5. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
6. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab. Arthritis Rheum 2003;48:1126-36.
7. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003;62:347-9.
8. Kruithof E, Van den Bosch F, Baeten D, De Keyser F, Mielants H, Veys EM. Structure modifying properties of TNF-alpha blockade with infliximab in psoriatic arthritis: a case report. Clin Rheumatol 2001;20:417.
9. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
10. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, et al. Reduction of chemokine levels and leucocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38-47.
11. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000;43:2391-6.
12. Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002;41:484-9.
13. McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, et al. IL-10 improves skin disease and modulates endothelial activation and leucocyte effector function in patients with psoriatic arthritis. J Immunol 2001;167:4075-82.
14. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-95.
15. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group preliminary criteria for classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218-27.
16. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
17. Baeten D, Van den Bosch F, Elewaut D, Stuer A, Veys EM, De Keyser F. Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol 1999;18:434-41.
18. Baeten D, Demetter P, Cuvelier C, Van den Bosch F, Kruithof E, Van Damme N, et al. Comparative study of synovial histology in rheumatoid arthritis, spondyloarthropathy and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000;59:945-53.
19. Baeten D, Demetter P, Cuvelier CA, Kruithof E, Van Damme N, De Vos M, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002;196:343-50.
20. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993;36:893-900.
21. Smeets TJ, Kraan MC, Versendaal J, Breedveld FC, Tak PP. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol 1999;26:2089-93.
22. Sanchez C, Domenech N, Vazquez J, Alonso F, Ezquerra A, Dominguez J, The porcine 2A10 antigen is homologous to human CD163 and related to macrophage differentiation. J Immunol 1999;162:5230-37.
23. Van den Heuvel MM, Tensen CP, van As JH, Van den Berg TK, Fluitsma DM, Dijkstra CD, et al. Regulation of CD163 on human macrophages: cross-linking of CD163 induces signalling and activation. J Leukoc Biol 1999;66:858-66.
24. Baeten D, Moller HJ, Delanghe J, Veys EM, Moestrup SK, De Keyser F. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004;50:1611-23.
25. Vandooren B, Kruithof E, Yu DTY, Rihl M, Gu J, De Rycke L, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy. Arthritis Rheum 2004;50:2942-53.
26. Ory P, Sharp JT, Salonen D, Rubenstein J, Mease PJ, Kivitz AJ, et al. Etanercept (Enbrel®) inhibits radiographic progression in patients with psoriatic arthritis [abstract]. Arthritis Rheum 2002;46:S196.
27. Baeten D, Kruithof E, De Rycke L, Hoffman LEA, Vandooren B, Mielants H, et al. Differential histopathology of the synovial membrane in spondyloarthropathy subtypes and rheumatoid arthritis [abstract]. Arthritis Rheum 2002;46:S440.